Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
BRCA Mutation: early-phase trial registry
2 of 5 indexed BRCA Mutation trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
BRCA Mutation: 5 US clinical trials tracked, 2 recruiting.
BRCA Mutation is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Pamela Munster, running 1 of these trials.
Enrollment posture brief
Registry condition brca-mutation
OPEN 2 | RECR 40% | LATE 1 | EARLY 2 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
BRCA Mutation lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for BRCA Mutation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
BRCA Mutation is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates BRCA Mutation research.
Pamela Munster accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical BRCA Mutation enrolment sits around 120 participants.
Median target enrolment is 120 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
BRCA Mutation splits between interventional and observational designs.
3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
858 Therapeutics
NCT06395519
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Pamela Munster
NCT06177171
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
AstraZeneca
NCT01844986
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
NCT05692596
Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer
Abramson Cancer Center at Penn Medicine
NCT06436248
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on BRCA Mutation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on BRCA Mutation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this BRCA Mutation page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 BRCA Mutation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pamela Munster sponsors the most BRCA Mutation trials on record, review their full trial history before evaluating a specific study. See Pamela Munster's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This BRCA Mutation condition card totals 5 registered trials; most-linked intervention Olaparib 300mg tablets; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.